P00749 (UROK_HUMAN) Homo sapiens (Human)

Urokinase-type plasminogen activator UniProtKBInterProSTRINGInteractive Modelling

431 aa; Sequence (Fasta) ; (Isoform 2)

Available Structures

155 Experimental Structures

DescriptionPDB IDOligo-stateRangeSeq id (%)Ligands
Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine P… Heteromer
164-424
100CIT;655;
ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRU… Heteromer
164-424
100CIT;130;
Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala1… Heteromer
164-423
100ESI;CIT;
Low molecular weigth human Urokinase type Plasminogen activator 2-[6-(3'-Aminomethyl-biphenyl-3-ylo… Heteromer
168-423
100438;
Crystal structure of human Urokinase-type plasminogen activator in complex with bicycle peptide inh… Heteromer
179-425
99.19SO4;PEG;EDO;1PE;ZBR;
Crystal Structure of a Michaelis Complex between Plasminogen Activator Inhibitor-1 and Urokinase-ty… Heteromer
P05121;
179-425
98.78SO4;
Crystal structure of uPA in complex with a camelid-derived antibody fragment Heteromer
179-424
99.19GOL;SO4;TWN;MES;
Human urokinase-type Plasminogen Activator (uPA) in complex with a bicyclic peptide inhibitor (UK18… Heteromer
179-423
99.18SO4;CL;P6G;ZBR;
Human urokinase-type Plasminogen Activator (uPA) in complex with a bicyclic peptide inhibitor (UK18… Heteromer
179-423
99.18SO4;CL;P6G;ZBR;
The crystal structure of uPA in complex with the Fab fragment of mAb-112 Heteromer
184-424
99.09SO4;
Structure of urokinase receptor, urokinase and vitronectin complex Heteromer
P04004; Q03405;
28-152
99.2NAG;NAG;
Structure of anti-uPAR Fab ATN-658 in complex with uPAR Heteromer
P04004; Q03405;
28-152
99.2NAG;MAN;NAG;
Structure of urokinase receptor, urokinase and vitronectin complex Heteromer
P04004; Q03405;
29-152
99.19NAG;NAG;
Crystal structure of stabilized human uPAR mutant in complex with ATF Heteromer
Q03405;
30-152
99.19NAG;NAG;
Structure of Human Urokinase Plasminogen Activator in Complex with Urokinase Receptor and an anti-u… Heteromer
Q03405; Q52L64; Q924Q0;
31-152
99.18NAG;NAG;SO4;ETX;EDO;PGE;NDG;PG4;
Crystal structure of ATF-urokinase receptor complex Heteromer
Q03405;
31-152
99.18NAG;SO4;
ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRU…homo-2-mer160-423
100CIT;135;
ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRU…homo-2-mer160-423
100CIT;133;
ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRU…homo-2-mer160-423
100CIT;136;
STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKI…homo-2-mer164-426
100FLC;ESP;
STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKI…homo-2-mer164-426
100FLC;ESI;
STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKI…homo-2-mer164-426
100FLC;ESI;
ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRU…homo-2-mer164-424
100CIT;132;
Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala1…homo-2-mer164-424
100CR9;CIT;
Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala1…homo-2-mer164-424
100696;CIT;
ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRU…homo-2-mer164-424
100CIT;130;
ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRU…homo-2-mer164-424
100CIT;134;
A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK …homo-2-mer164-423
100CIT;BMZ;
A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK …homo-2-mer164-423
100120;CIT;
A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK …homo-2-mer164-423
100123;CIT;
STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKI…homo-2-mer164-423
100FLC;BEN;
LMW U-PA Structure complexed with EGRCMK (GLU-GLY-ARG Chloromethyl Ketone)homo-2-mer168-426
1000GJ;
Urokinase-Type Plasminogen Activator Inhibitor Complex with a 1-(7- SULPHOAMIDOISOQUINOLINYL)GUANID…monomer165-427
99.61QGG;
Tranexamic Acid is an Active Site Inhibitor of Urokinase Plasminogen Activatormonomer166-424
100.0NO3;AMH;
Crystal structure of complex of urokinase and a upain-1 variant(W3F) in pH7.4 conditionmonomer179-426
99.19
The crystal structure of uPA complex with peptide inhibitor MH027 at pH4.6monomer179-426
99.19SO4;PG4;
Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-T…monomer179-426
99.6ACT;SO4;L1R;
Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-T…monomer179-426
99.6ACT;VG2;
Crystal structure of uPA in complex with upain-2-3-W3Amonomer179-426
99.19ALA;CYS;
Crystal structure of uPA in complex with 6-amidino-2-naphtholmonomer179-426
99.197R8;SO4;PGE;
Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-T…monomer179-426
99.6ACT;L1O;
Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-T…monomer179-426
99.6ACT;SO4;505;
Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-T…monomer179-426
99.6ACT;D55;
Synthesis of a Weak Basic uPA Inhibitor and Crystal Structure of Complex with uPAmonomer179-426
99.1911E;PG6;
Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-T…monomer179-426
99.6ACT;D56;
The crystal structure of uPA complex with peptide inhibitor MH027 at pH7.4monomer179-426
99.19SO4;
The crystal structure of upain-1-W3A in complex with uPA at pH7.4monomer179-425
99.19SO4;P6G;
The complex crystal Structure of Urokianse and 2-Aminobenzothiazolemonomer179-425
99.59SO4;ABV;
The crystal structure of mupain-1-17 in complex with murinised human uPA at pH4.6monomer179-425
98.78SO4;PGE;MRZ;
Crystal structure of human Urokinase-type plasminogen activator in complex with bicycle peptide inh…monomer179-425
99.191PE;EDO;NH2;ZBR;
Crystal structure of complex of urokinase and a upain-1 variant(W3A) in pH4.6 conditionmonomer179-425
99.19
UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-BENZAMIDINE COMPLEXmonomer179-425
99.59SO4;BEN;
UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN INHIBITOR COMPLEXmonomer179-425
99.59SO4;AGB;
The crystal structure of mupain-1-16 in complex with murinised human uPA at pH7.4monomer179-425
98.78MRZ;
Urokinase type plasminogen activatormonomer179-425
99.59SI1;SO4;
The crystal structure of mupain-1--16-IG in complex with murinised human uPA at pH7.4monomer179-425
98.78MRZ;
Urokinase Plasminogen Activator B-Chain-JT463 Complexmonomer179-425
99.59SO4;7IN;
UROKINASE TYPE PLASMINOGEN ACTIVATORmonomer179-425
99.59SM1;SO4;
Urokinase type plasminogen activatormonomer179-425
99.59SJ1;SO4;
UROKINASE TYPE PLASMINOGEN ACTIVATORmonomer179-425
99.59SO4;SK1;
Urokinase plasminogen activator B-chain-GPPE complexmonomer179-425
99.59SO4;4PG;
The crystal structure of mupain-1-IG in complex with murinised human uPA at pH7.4monomer179-425
98.78
The crystal structure of mupain-1-12 in complex with murinised human uPA at pH7.4monomer179-425
98.78PL0;
The crystal structure of mupain-1-17 in complex with murinised human uPAmonomer179-425
98.78MRZ;SO4;
UROKINASE TYPE PLASMINOGEN ACTIVATORmonomer179-425
99.59SO4;SH1;
The crystal structure of mupain-1 in complex with murinised human uPA at pH7.4monomer179-425
98.78
The crystal structure of uPA complex with peptide inhibitor MH036 at pH4.6monomer179-425
99.19
Urokinase Plasminogen Activator B-Chain-J435 Complexmonomer179-425
99.59SO4;2IN;
UROKINASE TYPE PLASMINOGEN ACTIVATORmonomer179-425
99.59SL1;
Urokinase Plasminogen Activator B-Chain-JT464 Complexmonomer179-425
99.59SO4;5IN;
UROKINASE PLASMINOGEN ACTIVATOR B CHAIN-UKI-1D COMPLEXmonomer179-425
99.59SO4;UKP;
The crystal structure of uPA in complex with 4-Bromobenzylamirne at pH4.6monomer179-424
99.19PZH;SO4;PGE;
The crystal structure of upain-1-W3A in complex with uPA at pH9.0monomer179-424
99.19SO4;P6G;
The crystal structure of upain-1-W3A in complex with uPA at pH5.5monomer179-424
99.18SO4;PG4;
Crystal structure of uPA in complex with upain-2-2monomer179-424
99.19SO4;
Structure of PAItrap, an uPA mutantmonomer179-424
97.97SO4;PGE;GOL;
Crystal Structure of the Urokinasemonomer179-424
99.191U2;SO4;ACT;GOL;
Crystal Structure of the Urokinasemonomer179-424
99.19SO4;SIN;GOL;ACT;675;
Crystal structure of uPA in complex with upain-2-2-W3Amonomer179-424
99.19
uPA-HMAmonomer179-424
99.19HMX;SO4;
Crystal Structure of the Urokinasemonomer179-424
99.19239;SIN;SO4;ACT;GOL;
uPA-6F-HMAmonomer179-424
99.19EAU;SO4;
Crystal structure of uPA_H99Y in complex with 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(furan-2-y…monomer179-424
98.78EAU;SO4;
Crystal Structure of the Urokinasemonomer179-424
99.199UP;SO4;GOL;ACT;
The crystal structure of upain-1-W3A in complex with inactive uPA (uPA-S195A) at pH7.4monomer179-424
98.78
Crystal Structure of the Urokinasemonomer179-424
99.194UP;SO4;SIN;GOL;15P;ACT;
The crystal structure of mupain-1-16-D9A in complex with murinised human uPA at pH7.4monomer179-424
98.78MRZ;
The crystal structure of human urokinase-type plasminogen activator catalytic domainmonomer179-424
99.19SO4;P6G;
Crystal structure of uPA in complex with 4-guanidinobenzoic acidmonomer179-424
99.19PGE;GBS;
Crystal Structure of the Urokinasemonomer179-424
99.19SO4;ACT;1UP;
The crystal structure of uPA in complex with 4-Bromobenzylamirne at pH7.4monomer179-424
99.19PZH;SO4;
Crystal Structure of the Urokinasemonomer179-424
99.19UI3;SO4;GOL;NA;SIN;
Crystal Structure of the Urokinasemonomer179-424
99.196UP;SIN;SO4;NA;
Crystal Structure of the Urokinasemonomer179-424
99.197UP;SIN;SO4;GOL;ACT;
Crystal Structure of the Urokinasemonomer179-424
99.198UP;SIN;SO4;GOL;ACT;
The complex crystal Structure of Urokianse and 5-nitro-1H-indole-2-amidinemonomer179-424
99.59B25;SO4;
Crystal Structure of the Urokinasemonomer179-424
99.191U9;SIN;SO4;ACT;GOL;
New Pharmacophore for Serine Protease Inhibition Revealed by Crystal Structure of Human Urokinase-t…monomer179-424
99.17
Crystal Structure of the Urokinasemonomer179-424
99.192UP;ACT;SIN;SO4;
Crystal structure of uPA_H99Y in complex with 3-azanyl-5-(azepan-1-yl)-N-[bis(azanyl)methylidene]-6…monomer179-424
98.78HMX;SO4;
Crystal structure of uPA in complex with S2444monomer179-424
99.197YF;
Crystal Structures of Urokinase-type Plasminogen Activator in Complex with 4-(Aminomethyl) Benzoic …monomer179-424
99.164AL;SO4;PGE;
The Crystal Structures of 2-Aminobenzothiazole-based Inhibitors in Complexes with Urokinase-type Pl…monomer179-424
99.162BS;
Crystal structure of uPA in complex with quercetinmonomer179-424
99.19QUE;PG6;
The crystal structure of uPA in complex with 4-Iodobenzylamine at pH7.4monomer179-423
99.18ZXI;
Crystal Structure and Binding Epitopes of Urokinase-type Plasminogen Activator (C122A/N145Q) in com…monomer179-423
99.13SO4;1PE;PEG;
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK7…monomer179-423
99.18SO4;GOL;ACT;ZBR;
Human urokinase-type plasminogen activator uPA in complex with the two-disulfide bridge peptide UK5…monomer179-423
99.18SO4;NA;CL;P6G;GOL;
Substituted 2-Naphthamidine inhibitors of urokinasemonomer179-423
99.18SO4;675;
Substituted 2-Naphthamidine Inhibitors of Urokinasemonomer179-423
99.18SO4;239;
uPA-BB2-50Fmonomer179-423
99.1850I;
Crystal structure of uPA in complex with 3,5-bis(azanyl)-6-(1-benzofuran-2-yl)-N-carbamimidoyl-pyra…monomer179-423
99.189XF;SO4;
uPA-BB2-28Fmonomer179-423
99.1828I;
uPA-31Fmonomer179-423
99.1832I;
Crystal Structure and Binding Epitopes of Urokinase-type Plasminogen Activator (C122A/N145Q/S195A) …monomer179-423
98.74SO4;BEN;PG4;PEG;
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK9…monomer179-423
99.18SO4;ACT;GOL;29O;
Crystal structure of uPA in complex with upain-2-4-W3Amonomer179-423
99.18
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK6…monomer179-423
99.18SO4;ACT;
uPA-HMAmonomer179-423
99.189X9;SO4;
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK6…monomer179-423
99.18SO4;ACT;
Crystal structure of uPA in complex with upain-2-4monomer179-423
99.18
Crystal structure of bicyclic peptide UK729 bound as an acyl-enzyme intermediate to urokinase-type …monomer179-423
99.18SO4;ACT;ZBR;GOL;
Substituted 2-Naphthamidine Inhibitors of Urokinasemonomer179-423
99.18SO4;UI2;
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK8…monomer179-423
99.18SO4;GOL;29N;
Crystal Structure and Binding Epitopes of Urokinase-type Plasminogen Activator (C122A/N145Q/S195A) …monomer179-423
98.78SO4;PG4;PL0;
Crystal structure of inactive uPA in complex with nafamostatmonomer179-423
98.787RF;
uPA-NU-09Fmonomer179-423
99.1809I;
Substituted 2-Naphthamidine Inhibitors of Urokinasemonomer179-423
99.59UI3;
The crystal structure of uPA in complex with HMA-55Fmonomer179-423
99.18H55;
uPA-BB2-27Fmonomer179-423
99.1827I;
Potent and selective bicyclic peptide inhibitor (UK18) of human urokinase-type plasminogen activato…monomer179-423
99.18ZBR;
uPA-BB2-94Fmonomer179-423
99.1894I;
Substituted 2-Naphthamidine Inhibitors of Urokinasemonomer179-423
99.18SO4;UI1;
Crystal structure of uPA in complex with cleaved camostatmonomer179-423
99.18GBS;PGE;
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK6…monomer179-423
99.18SO4;ACT;GOL;
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK6…monomer179-423
99.18SO4;GOL;ACT;CL;
Crystal structure of uPA in complex with nafamostatmonomer179-423
99.18GBS;PGE;
Substituted 2-Naphthamadine inhibitors of Urokinasemonomer179-423
99.59745;
UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-AMILORIDE COMPLEXmonomer179-423
99.59SO4;AMR;
Crystal structure of uPA-S195A in complex with S2444monomer179-423
98.787YR;
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK6…monomer179-423
99.18SO4;ACT;
Crystal structure of uPA_H99Y in complex with 31Fmonomer179-423
98.7832I;
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK6…monomer179-423
99.18SO4;
Substituted 2-Naphthamidine inhibitors of urokinasemonomer179-423
99.59497;
Crystal Structures of Urokinase-type Plasminogen Activator in Complex with 4-(Aminomethyl) Benzoic …monomer179-423
99.164AZ;SO4;
Crystal structure of uPA in complex with 3,5-bis(azanyl)-N-carbamimidoyl-6-(2,4-dimethoxypyrimidin-…monomer179-423
99.189XC;
Crystal structure of uPA_H99Y in complex with 50Fmonomer179-423
98.7850I;
Substituted 2-Naphthamidine Inhibitors of Urokinasemonomer179-423
99.59303;
Substituted 2-Naphthamidine Inhibitors of Urokinasemonomer179-423
99.59426;
uPA-BB2-30Fmonomer179-423
99.1830I;
Crystal structure of human microurokinase in complex with 2-amino-5-hydroxy-benzimidazolemonomer179-423
99.18SO4;172;
Substituted 2-Naphthamidine Inhibitors of Urokinasemonomer179-423
99.59155;
SOLUTION STRUCTURE OF THE AMINO TERMINAL FRAGMENT OF UROKINASE-TYPE PLASMINOGEN ACTIVATORmonomer26-155
99.23FUC;
Crystal structure of the free aminoterminal fragment of urokinase type plasminogen activator (ATF)monomer30-152
99.19
SEQUENTIAL 1H NMR ASSIGNMENTS AND SECONDARY STRUCTURE OF THE KRINGLE DOMAIN FROM UROKINASEmonomer69-153
98.82

4 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
2vnt.3.Amonomer0.83166-426
QGG;99.64
3laq.1.Amonomer0.6728-151
71.43
5edm.1.Amonomer0.6069-428
29.48
1urk.1.Amonomer0.5427-153
99.21

5 SWISS-MODEL models built on isoform sequence

IsoformTemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 22vnt.3.Amonomer0.83149-409
QGG;99.64
Isoform 23bt2.1.Amonomer0.6812-135
97.60
Isoform 21urk.1.Amonomer0.5912-136
98.40
Isoform 24nzq.1.Amonomer0.5712-409
28.35
Isoform 25edk.1.Amonomer0.5412-411
28.20